Pharming Group N.V. ADR (PHAR) Stock Price, Quote & News

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 71 524 7400

Fax: 31 71 524 7445

Website: www.pharming.com

Address:

Darwinweg 24, Leiden, Netherlands

Noobnr1 Nov. 13 at 4:15 PM

$BEAM C’mon let’s go again thanks $PFE $NYXH numbers after hours 🚀🚀🚀 $PHAR 🥇🐇

0 · Reply

Declan1NL Nov. 12 at 3:15 PM

$PHAR go on Pharming $20 she waits!!

2 · Reply

Investor203 Nov. 12 at 1:45 PM

$PHAR $TERN ummm. Lol. Hold long. $BKYI to hit $1 then $3 to $5 in a year or sooner!

0 · Reply

ryan_moore94a Nov. 12 at 11:44 AM

$PHAR biotech setup.

0 · Reply

Dutchindo Nov. 11 at 10:01 AM

$PHAR AEX📉NDQ📈

0 · Reply

Doozio Nov. 11 at 2:18 AM

$PHAR huckleberries n $$$ patterns. Faatch 💣 or 🌙…….

0 · Reply

Gabriel1234 Nov. 10 at 9:41 PM

$PHAR https://www.beurs.nl/Nieuws/840110/Jefferies-verhoogt-koersdoel-Pharming.aspx

0 · Reply

Investor203 Nov. 10 at 8:46 PM

$PHAR $TERN .. now I am very bullish on $BKYI and $GPUS . $5 in next 180-365 days

0 · Reply

Noobnr1 Nov. 10 at 5:47 PM

$GNFT 🚀🚀 $PHAR 🚀🚀$NYXH 🚀🚀 Winners for today… big winners for the future 🥂🚀🥂🚀🥂

0 · Reply

Noobnr1 Nov. 10 at 5:28 PM

$NYXH 🚀💎 $PHAR 🐇🚀 $DVAX 🚀🤞 C’mon big ones $GILD and $PFE 🙏🙏

0 · Reply

Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 3:00 AM EDT - 15 days ago

Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London

Oct 23, 2025, 2:00 AM EDT - 22 days ago

Pharming Group to report third quarter 2025 financial results and provide business update on November 6

Oct 20, 2025, 2:00 AM EDT - 25 days ago

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Oct 6, 2025, 11:35 AM EDT - 5 weeks ago

Pharming Group provides update on previously announced G&A expense reduction plan

Oct 1, 2025, 1:00 AM EDT - 6 weeks ago

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years

Sep 10, 2025, 1:00 AM EDT - 2 months ago

Pharming Group promoted to the Euronext AMX® index

Sep 3, 2025, 2:00 AM EDT - 2 months ago

Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 1:00 AM EDT - 2 months ago

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Aug 4, 2025, 2:00 AM EDT - 3 months ago

Pharming Group to participate in August investor conference

Aug 1, 2025, 3:04 PM EDT - 3 months ago

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 1:00 AM EDT - 3 months ago

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Jul 17, 2025, 2:00 AM EDT - 4 months ago

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Jun 24, 2025, 1:00 AM EDT - 5 months ago

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Jun 11, 2025, 11:15 AM EDT - 5 months ago

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

May 28, 2025, 2:00 AM EDT - 6 months ago

Pharming Group to participate in June investor conferences

May 9, 2025, 8:50 AM EDT - 6 months ago

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 8, 2025, 1:00 AM EDT - 6 months ago

Pharming Group reports first quarter 2025 financial results and provides business update

Apr 30, 2025, 11:45 AM EDT - 7 months ago

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Apr 24, 2025, 2:00 AM EDT - 7 months ago

Pharming Group to report first quarter 2025 financial results on May 8

Apr 23, 2025, 3:30 AM EDT - 7 months ago

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Apr 3, 2025, 1:00 AM EDT - 8 months ago

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Mar 28, 2025, 3:00 AM EDT - 8 months ago

Pharming Group to participate in April investor conferences

Mar 13, 2025, 7:44 PM EDT - 8 months ago

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 2:00 AM EDT - 8 months ago

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Mar 4, 2025, 9:15 AM EST - 9 months ago

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Feb 7, 2025, 4:00 PM EST - 10 months ago

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Jan 21, 2025, 12:00 PM EST - 10 months ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 1:00 AM EST - 10 months ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Dec 15, 2024, 1:45 PM EST - 11 months ago

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 11, 2024, 9:34 AM EST - 1 year ago

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Nov 5, 2024, 2:00 AM EST - 1 year ago

Pharming Group to participate in November investor conference

Oct 24, 2024, 1:44 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 10, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Sep 26, 2024, 1:00 AM EDT - 1 year ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group to participate in September investor conferences

Aug 2, 2024, 3:26 PM EDT - 1 year ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 1:00 AM EDT - 1 year ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Jul 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

May 30, 2024, 4:44 PM EDT - 1 year ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 21, 2024, 11:30 AM EDT - 1 year ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 20, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to participate in May investor conference

May 15, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

May 12, 2024, 9:19 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

Apr 24, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report first quarter 2024 financial results on May 8

Apr 24, 2024, 1:00 AM EDT - 1 year ago

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Apr 19, 2024, 12:43 PM EDT - 1 year ago

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Apr 18, 2024, 9:04 AM EDT - 1 year ago

Pharming Group announces the placement of €100 million convertible bonds due 2029

Apr 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Noobnr1 Nov. 13 at 4:15 PM

$BEAM C’mon let’s go again thanks $PFE $NYXH numbers after hours 🚀🚀🚀 $PHAR 🥇🐇

0 · Reply

Declan1NL Nov. 12 at 3:15 PM

$PHAR go on Pharming $20 she waits!!

2 · Reply

Investor203 Nov. 12 at 1:45 PM

$PHAR $TERN ummm. Lol. Hold long. $BKYI to hit $1 then $3 to $5 in a year or sooner!

0 · Reply

ryan_moore94a Nov. 12 at 11:44 AM

$PHAR biotech setup.

0 · Reply

Dutchindo Nov. 11 at 10:01 AM

$PHAR AEX📉NDQ📈

0 · Reply

Doozio Nov. 11 at 2:18 AM

$PHAR huckleberries n $$$ patterns. Faatch 💣 or 🌙…….

0 · Reply

Gabriel1234 Nov. 10 at 9:41 PM

$PHAR https://www.beurs.nl/Nieuws/840110/Jefferies-verhoogt-koersdoel-Pharming.aspx

0 · Reply

Investor203 Nov. 10 at 8:46 PM

$PHAR $TERN .. now I am very bullish on $BKYI and $GPUS . $5 in next 180-365 days

0 · Reply

Noobnr1 Nov. 10 at 5:47 PM

$GNFT 🚀🚀 $PHAR 🚀🚀$NYXH 🚀🚀 Winners for today… big winners for the future 🥂🚀🥂🚀🥂

0 · Reply

Noobnr1 Nov. 10 at 5:28 PM

$NYXH 🚀💎 $PHAR 🐇🚀 $DVAX 🚀🤞 C’mon big ones $GILD and $PFE 🙏🙏

0 · Reply

Noobnr1 Nov. 10 at 5:53 AM

$PFE Metsera is ours 💎💪🚀 $DVAX $GILD $OMER $PHAR also has a lot interesting stuff for the big guys 🥂

0 · Reply

DARKP00L Nov. 6 at 2:11 PM

$PHAR 08:52 on Nov. 06 2025 Pharming Group shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates. #tradeideas

1 · Reply

DARKP00L Nov. 6 at 1:56 PM

1 · Reply

Noobnr1 Nov. 6 at 1:53 PM

$PHAR The diamand 💎is launched🚀 Hello $PFE $DVAX let’s go $GILD yes we can get higher 😁🚀

0 · Reply

Ruconestor Nov. 6 at 6:12 AM

$PHAR Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow

0 · Reply

Investor203 Nov. 3 at 5:35 PM

$PHAR $TERN I think I was correct! LoL

0 · Reply

justiceforb_85 Oct. 26 at 11:40 PM

$PHAR any updates on progress for leniolisib in CVID trial?

0 · Reply

Gabriel1234 Oct. 23 at 7:09 PM

$PHAR https://www.marketwatch.com/investing/stock/phar

0 · Reply

Gabriel1234 Oct. 20 at 9:57 PM

$PHAR Positive results highlighted: The press release specifically mentions “positive new clinical, economic, and comparative data” — implying that results are favorable and could support stronger positioning versus competitors (e.g., Sebetralstat for HAE). Broader awareness: Presenting at ACAAI boosts visibility among specialists, potentially helping future prescriptions and market adoption for both drugs. Long-term signal: It strengthens Pharming’s reputation in rare disease research, which could attract new partnerships or clinical collaborations.

1 · Reply

Gabriel1234 Oct. 20 at 9:56 PM

$PHAR Scientific recognition: Having 12 abstracts accepted at a major international conference (ACAAI 2025) demonstrates strong recognition of Pharming’s research quality and scientific credibility in rare diseases. Pipeline strength: The data covers both of Pharming’s marketed drugs — RUCONEST®, already approved for hereditary angioedema (HAE) Joenja® (leniolisib), approved for APDS — and shows ongoing clinical, real-world, and economic research, suggesting continued development and relevance.

0 · Reply

Gabriel1234 Oct. 20 at 9:55 PM

$PHAR Pharming Group N.V. announced that 12 scientific abstracts have been accepted for presentation at the 2025 ACAAI Annual Scientific Meeting in Orlando, Florida (November 6–10, 2025). Five posters will share new data on RUCONEST® for the on-demand treatment of hereditary angioedema (HAE), while seven focus on Joenja® (leniolisib) and its real-world effectiveness in treating APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome). The studies highlight clinical outcomes, cost-effectiveness, quality of life, and patient/caregiver experiences.Pharming’s Chief Medical Officer, Anurag Relan, emphasized that these presentations reflect the company’s commitment to advancing care for patients with rare diseases.

0 · Reply

Gabriel1234 Oct. 20 at 1:55 PM

$PHAR https://www.marketwatch.com/press-release/pharming-group-announces-presentations-at-2025-acaai-annual-scientific-meeting-showcasing-new-data-across-rare-disease-portfolio-07005207?mod=mw_quote_news_seemore

0 · Reply

Market Cap	1.18B
Revenue (ttm)	297.20M
Net Income (ttm)	-11.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	75.19
Profit Margin	-3.98%
Debt to Equity Ratio	0.02

Volume	17,100
Avg Vol	15,200
Day's Range	N/A - N/A
Shares Out	68.52M
Stochastic %K	97%
Beta	0.03
Analysts	Strong Sell
Price Target	$31.00